Biotech Losers: Discovery Laboratories (NASDAQ:DSCO), CEL-SCI Corporation (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), La Jolla Pharmaceutical (NASDAQ:LJPC)

Discovery Laboratories, Inc. (NASDAQ:DSCO) has been upgraded by TheStreet Ratings from sell to hold. Discovery Laboratories, Inc. (NASDAQ:DSCO) stock performance was -6.01% in last session and finished the day at $2.19. Traded volume was 1,245,476 million shares in the last session and the average volume of the stock remained 589.46 million shares. The beta of the stock remained 1.35. Discovery Laboratories, Inc. (NASDAQ:DSCO) insider ownership … Continue reading Biotech Losers: Discovery Laboratories (NASDAQ:DSCO), CEL-SCI Corporation (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), La Jolla Pharmaceutical (NASDAQ:LJPC)

Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Shares of Neuralstem (NYSEMKT:CUR) , a clinical-stage biopharmaceutical company focused on treating central nervous system disorders through neural stem-cell therapies, advanced as much as 13% after reporting final phase 1 results utilizing NSI-566 in treating amyotrophic lateral sclerosis. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 12.05% in last session and finished the day at $4.37. Traded volume was 4,029,043 million shares in the last session and … Continue reading Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Tengion, Inc. (OTCMKTS:TNGN) on Mar. 3 issued notices to the holders (the “2012 Investors”) of senior secured notes issued on October 2, 2012 and to the holders (the “2013 Investors” and together with the 2012 Investors, the “Investors” and each, an “Investor”) of senior secured notes issued on June 28, 2013 stating that the Company plans to issue shares of common stock, $0.001 par value … Continue reading Biotech Unusual Volume: Tengion (OTCMKTS:TNGN), Alseres Pharmaceuticals (OTCMKTS:ALSE), Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN)

Bristol-Myers Squibb & Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that the FDA has approved an additional indication of Bristol’s anti-blood clot medicine, Eliquis. Pfizer Inc. (NYSE:PFE) stock performance was 0.35% in last session and finished the day at $31.23. Traded volume was 27.11 million shares in the last session and the average volume of the stock remained 27.87 million shares. The beta of … Continue reading Biotech active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG), Ariad Pharmaceuticals (NASDAQ:ARIA)

Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE) stock performance was 27.14% in last session and finished the day at $11.15. Traded volume was 295,227.00 shares in the last session and the average volume of the stock … Continue reading Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)

Relypsa, Inc. (NASDAQ:RLYP) is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Relypsa Inc. (NASDAQ:RLYP) stock performance was 2.66% in last session and finished the day at $43.62. Traded volume was 126,739.00 shares in the last session and the average volume of the stock remained 113,686.00 shares. Relypsa … Continue reading Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)